Genprex, Inc. (41)
Browse by Contract Category
Contracts
-
Exclusive License Agreement, dated December 29, 2022
(Filed With SEC on January 5, 2023)
-
Equity Distribution Agreement, dated November 18, 2022 by and among Genprex, Inc. and JMP Securities LLC
(Filed With SEC on November 18, 2022)
-
Form of Indemnity Agreement by and between the Company and its directors and officers, dated as of May 17, 2022
(Filed With SEC on August 12, 2022)
-
First Amendment to Executive Employment Agreement dated as of March 24, 2021 by and between Genprex, Inc. and Catherine Vaczy
(Filed With SEC on March 25, 2021)
-
Placement Agency Agreement dated February 8, 2021
(Filed With SEC on February 9, 2021)
-
Exclusive License Agreement, dated November 22, 2022
(Filed With SEC on November 28, 2022)
-
First Amendment to Exclusive License Agreement, dated August 17, 2022
(Filed With SEC on August 22, 2022)
-
Warrant Agreement with Bear Creek Capital, LLC, dated as of July 1, 2022
(Filed With SEC on August 12, 2022)
-
Description of Registrant's Securities
(Filed With SEC on March 30, 2022)
-
Form of Warrant Agreement, dated as of July 1, 2021
(Filed With SEC on November 15, 2021)
-
Option Award Agreement between Genprex, Inc. and Mark S. Berger, M.D. dated September 27, 2021
(Filed With SEC on September 28, 2021)
-
Offer Letter between Genprex, Inc. and Mark S. Berger, M.D
(Filed With SEC on September 28, 2021)
-
Offer Letter between Genprex, Inc. and Hemant Kumar, PhD
(Filed With SEC on September 28, 2021)
-
Option Award Agreement between Genprex, Inc. and Hemant Kumar, PhD dated September 27, 2021
(Filed With SEC on September 28, 2021)
-
Form of Warrant Agreement, dated as of February 10, 2021
(Filed With SEC on May 17, 2021)
-
Amendment No. 1 to Patent and Technology License Agreement, dated March 3, 2021, by and between the Registrant and The University of Texas M.D. Anderson Cancer Center
(Filed With SEC on March 26, 2021)
-
Description of Registrant's Securities
(Filed With SEC on March 26, 2021)
-
Amended and Restated Warrant Agreement, dated August 10, 2020, issued to DABS Advanced Biotech Solutions, LLC
(Filed With SEC on March 26, 2021)
-
Amended and Restated Warrant Agreement, dated August 10, 2020, issued to DABS Advanced Biotech Solutions, LLC
(Filed With SEC on March 26, 2021)
-
Warrant Agreement, dated August 10, 2020, issued to Capital City Technical Consulting, Inc
(Filed With SEC on March 26, 2021)
-
First Amendment to Executive Employment Agreement dated as of March 24, 2021 by and between Genprex, Inc. and Michael Redman
(Filed With SEC on March 25, 2021)
-
Form of Securities Purchase Agreement dated February 8, 2021
(Filed With SEC on February 9, 2021)
-
Form of Securities Purchase Agreement dated December 22, 2020
(Filed With SEC on December 23, 2020)
-
Placement Agency Agreement dated December 22, 2020
(Filed With SEC on December 23, 2020)
-
Warrant Agreement, dated as of August 10, 2020, by and between Genprex, Inc. and Capital City Technical Consulting, Inc
(Filed With SEC on November 12, 2020)
-
Patent and Technology License Agreement dated as of May 4, 2020, by and between Genprex, Inc. and The Board of Regents of The University of Texas System
(Filed With SEC on May 14, 2020)
-
Separation Agreement dated as of April 27, 2020, by and between Genprex, Inc. and Julien L Pham, MD, MPH
(Filed With SEC on April 28, 2020)
-
Warrant Agreement dated as of April 24, 2020, by and between Genprex, Inc. and Cancer Revolution LLC
(Filed With SEC on April 28, 2020)
-
Description of Registrant's Securities
(Filed With SEC on March 30, 2020)
-
Amendment No. 1 to Stock Option Agreement dated as of March 18, 2020, by and between Genprex, Inc. and David E. Friedman
(Filed With SEC on March 24, 2020)
-
Amendment No. 1 to Stock Option Agreement dated as of March 18, 2020, by and between Genprex, Inc. and Robert W. Pearson
(Filed With SEC on March 24, 2020)
-
Executive Employment Agreement dated as of March 12, 2020, by and between Genprex, Inc. and Michael T. Redman
(Filed With SEC on March 23, 2020)
-
Executive Employment Agreement dated as of March 12, 2020, by and between Genprex, Inc. and Catherine M. Vaczy
(Filed With SEC on March 23, 2020)
-
Form of Securities Purchase Agreement dated February 19, 2020
(Filed With SEC on February 20, 2020)
-
Placement Agency Agreement dated February 19, 2020
(Filed With SEC on February 20, 2020)
-
EXCLUSIVE LICENSE AGREEMENT
(Filed With SEC on February 18, 2020)
-
Form of Securities Purchase Agreement dated January 23, 2020
(Filed With SEC on January 24, 2020)
-
Placement Agency Agreement dated January 23, 2020
(Filed With SEC on January 24, 2020)
-
Form of Securities Purchase Agreement dated January 16, 2020
(Filed With SEC on January 17, 2020)
-
Form of Warrant
(Filed With SEC on November 22, 2019)
-
Form of Securities Purchase Agreement dated November 20, 2019
(Filed With SEC on November 22, 2019)